Pharmaceutical formulary managers have a pressing need to manage their formulary budgets. Anticipating when drugs will face loss-of-exclusivity — when […]
This paper was originally published by Jian Du, Peixin Li, Qianying Guo, and Xiaoli Tang at Journal of Informetrics Volume 13, Issue
Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
Drug Spending in the US: Where the Money Actually Goes Read Post »
Businessman and investor Mark Cuban is probably best known as the owner of the Dallas Mavericks and as an investor
Mark Cuban Unexpected Leader in Orphan Drug Development Reform Read Post »
Anticipate the Future Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what’s next. We understand
Helping You Make Better Decisions: The DrugPatentWatch Design Philosophy Read Post »
The average time to market for a new drug is around 12 years, at a cost averaging $2.6 billion, according
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity
Business Continuity and Resiliency Planning for Biomedical and Research Organizations Read Post »
In November 2018, the Government Accountability Office (GAO) released a report titled “FDA Could Improve Designation Review Consistency; Rare Disease
Key Findings from GAO Report on Orphan Drug Approval Modernization Read Post »
This article was originally published by Nigel S. Clarke in World Patent Information Volume 54, Supplement, September 2018, Pages S4-S10 under
Get fresh news and insights, drug patent expirations & more…
